Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What’s Going On With The Stock?
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171.08%.
DraftKings Q1 Earnings Highlights: Sportsbook Posts Revenue Beat, EPS Beat, Raises Revenue, EBITDA Guidance
DraftKings reported first-quarter financial results that exceeded analyst expectations. The company also increased full year guidance for revenue and EBITDA.
Booking.Com’s Q1 Earnings Show Growth In Travel Demand – Here’s Why
Booking reported quarterly earnings of $20.39 per share which beat the analyst consensus estimate of $14.06 by 45.02%. The company reported quarterly sales of $4.415 billion which beat the analyst consensus estimate of $4.254 billion by 3.79% and represents a 16.86% percent increase over sales of $3.778 billion from the same period last year.
Apple Q2 Earnings Beats Muted Forecast On Services, Mac Strength: Installed Base At Fresh Record, Cupertino Announces Massive $110B Buyback
Apple rounded off the Magnificent Seven earnings of the week, with the tech giant managing to surpass a lowered bar.
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Revenue €62.4 Million Vs €58.6 Million YoY
Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 was €33.1 million, compared to an operating loss of €14.2 million for the three months ended
Block Stock Soars On Q1 Earnings, Strategic Bitcoin Investment: Details
Block, Inc. (NYSE:SQ) shares rose after the company reported its first-quarter financial results on Thursday.
Coinbase Q1 Earnings Highlights: Revenue Beat, Institutional Trading Volume Hits All-Time High, Bitcoin Totals 33% Of Trades
Cryptocurrency trading platform Coinbase Global (NASDAQ:COIN) reported first-quarter financial results after the market close Thursday.
Here are the key highlights.
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Eye Disease-Focused Glaukos’ ‘Investor Interest Should Continue To Gain Momentum:’ Analyst
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.
Peloton Stock Falls After Worse-Than-Expected Q3 Results, New Co-CEOs, Restructuring Plan
Peloton announced a restructuring program to include a reduction to its global headcount by approximately 15%, impacting roughly 400 Peloton team members. The company will also continue reducing its retail footprint and redesign its international go-to-market approach to be more targeted and efficient.